Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Cytokine profiling in patients with VCP-associated disease.

Authors: Dec, E  Rana, P  Katheria, V  Dec, R  Khare, M  Nalbandian, A  Leu, SY  Radom-Aizik, S  Llewellyn, K  BenMohamed, L  Zaldivar, F  Kimonis, V 
Citation: Dec E, etal., Clin Transl Sci. 2014 Feb;7(1):29-32. doi: 10.1111/cts.12117. Epub 2013 Oct 3.
Pubmed: (View Article at PubMed) PMID:24119107
DOI: Full-text: DOI:10.1111/cts.12117

Valosin containing protein (VCP) disease (also known as Inclusion Body Myopathy, Paget Disease of Bone and Frontotemporal Dementia [IBMPFD] syndrome) is caused by mutations in the gene encoding VCP classically affecting the muscle, bone and brain. Although the genetic cause has been identified, details regarding the pathogenesis of IBMPFD have not been fully determined. Muscle wasting observed in VCP disease is suggestive of cytokine imbalance. We hypothesized that dysfunctional protein homeostasis caused by VCP mutations leads to cytokine imbalances thereby contributing to the muscle wasting phenotype. Circulating levels of interleukin-4 (IL-4), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF a) and epidermal growth factor (EGF) were measured in plasma of patients with VCP disease or controls. TNF a and EGF were significantly altered in VCP disease as compared to control. TNF a was up-regulated, consistent with a cachexia phenotype and EGF levels were increased. No significant differences were observed in IL-4 and IL-6. Cytokine imbalances may be associated with VCP disease and may play a contributory role in VCP myopathy. Further understanding of how VCP dysfunction leads to aberrant protein homeostasis and subsequent cytokine imbalances may also aid in the understanding of other proteinopathies and in the development of novel treatments.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 10059681
Created: 2015-08-25
Species: All species
Last Modified: 2015-08-25
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.